MedTrace Logo

JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia

NCT03557970 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2021-12-02

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well edicotinib (JNJ-40346527) works in treating participants with acute myeloid leukemia that has come back or does not respond to treatment. JNJ-40346527 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia

Interventions

DRUG

Edicotinib

Given PO

OTHER

Pharmacokinetic Study

Correlative studies

Sponsors & Collaborators

  • Oregon Health and Science University

    collaborator OTHER

  • Janssen, LP

    collaborator INDUSTRY

  • The Leukemia and Lymphoma Society

    collaborator OTHER

  • OHSU Knight Cancer Institute

    lead OTHER

Principal Investigators

  • Elie Traer, MD · OHSU Knight Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-05
Primary Completion
2020-09-28
Completion
2020-09-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03557970 on ClinicalTrials.gov